Cost-Effectiveness of Three Alternative Boosted Protease Inhibitor-Based Second-Line Regimens in HIV-Infected Patients in West and Central Africa

BACKGROUND: While dolutegravir has been added by WHO as a preferred second-line option for the treatment of HIV infection, boosted protease inhibitor (bPI)-based regimens are still needed as alternative second-line options. Identifying optimal bPI-based second-line combinations is essential, given a...

Descripción completa

Detalles Bibliográficos
Autores principales: Boyer, S., Nishimwe, M. L., Sagaon-Teyssier, L., March, L., Koulla-Shiro, S., Bousmah, M.-Q., Toby, R., Mpoudi-Etame, M. P., Ngom Gueye, N. F., Sawadogo, A., Kouanfack, C., Ciaffi, L., Spire, B., Delaporte, E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7018873/
https://www.ncbi.nlm.nih.gov/pubmed/31273686
http://dx.doi.org/10.1007/s41669-019-0157-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7018873/
https://www.ncbi.nlm.nih.gov/pubmed/31273686
http://dx.doi.org/10.1007/s41669-019-0157-9

Ejemplares similares